Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Nov. 19, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... introduces a,new accessory, MPX(TM) (Multiplex) Blotting System, for ... can be incorporated into a,variety of assays including ... transduction pathway analysis, or any,other common Western blotting ... 7 x 8.5 cm., Processing is as ...
... Cardium Therapeutics,(Amex: CXM ) and ... that,InnerCool has entered into a exclusive commercialization ... distributor of medical products.,N.G.C. Medical primarily sells ... interventional cardiology markets. They also provide,in-service management ...
... REDWOOD CITY, Calif., June 19 Cardica, Inc.,(Nasdaq: ... Ph.D., the,company,s president and chief executive officer, is scheduled ... Thursday, June 26, 2008,at 12:30 p.m. Eastern Time. The ... To access the live and subsequently archived webcast ...
Cached Biology Technology:LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 6
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... (July 28, 2014)The Brain & Behavior Research Foundation ... and Freedman Prizes, recognizing exceptional clinical and basic ... by NARSAD Young Investigator Grants. The grants enable ... neurobiological and psychosocial research for the prevention, early ... affect one in four people. , Six young ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... common type of lung cancer are notoriously insensitive to ... cellular pathways that regulate responses to cisplatin have now ... the journal Cell Reports . The findings reveal ... how these patients will respond to chemotherapy, as well ...
... July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has ... metastatic melanoma. An article published in the current ... peer-reviewed journal from Mary Ann Liebert, Inc. ( http://www.liebertpub.com ... the most effective. The article is available free ...
... July 26, 2012 Congenital hypothyroidism is thyroid hormone ... to neurocognitive impairments in infants and children. Although ... daily during pregnancy for normal fetal thyroid hormone production ... 1,100 g to be the safe upper limit for ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns 2